Skip to main content
55°
Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
News
Local News
State News
Sports
Local Sports
Pro Sports
Lifestyle
Local Entertainment
Multimedia
Community Choice
Features
Special Sections
Local Events
Weather
Classifieds
Place Ad
Legal Notices
Place Call Legal
Search Call Legals
Place Times Legal
Search Times Legals
Public Notices
Obituaries
E-Edition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Latest News about Biogen Inc
Recent news which mentions Biogen Inc
< Previous
1
2
3
4
Next >
5 things to know before the stock market opens Tuesday
July 18, 2023
Tags
Business News
JPMorgan Chase & Co
Meta Platforms Inc
From
CNBC.com News
Eli Lilly expects FDA decision on Alzheimer's treatment donanemab by the end of the year
July 17, 2023
Tags
Biotech and Pharmaceuticals
Breaking news
Science
From
CNBC.com News
Medicare will pay for Alzheimer's drug Leqembi. What patients and doctors should know
July 08, 2023
Tags
Eisai Co Ltd
Health care industry
Breaking News: Business
From
CNBC.com News
Sales of Alzheimer’s drug Leqembi may be slow initially but could pick up in 2024
July 07, 2023
Tags
Pharmaceuticals
Companies
Eisai Co Ltd
From
CNBC.com News
Stocks making the biggest moves midday: Rivian, Levi Strauss, Biogen, First Solar and more
July 07, 2023
Tags
First Solar Inc
Alibaba Group Holding Ltd
stocks
From
CNBC.com News
Stocks making the biggest premarket moves: Levi Strauss, Biogen, Alibaba and more
July 07, 2023
Tags
Meta Platforms Inc
Costco Wholesale Corp
Finance
From
CNBC.com News
Japanese pharma Eisai slides 4% despite FDA approval for Alzheimer's drug
July 07, 2023
Tags
Social issues
Eisai Co Ltd
Pharmaceuticals
From
CNBC.com News
FDA approves Alzheimer’s drug Leqembi, paving way for broader Medicare coverage
July 06, 2023
Tags
Business News
Biotechnology
US: News
From
CNBC.com News
Stocks making the biggest moves midday: JD.Com, Biogen, Oracle and more
June 13, 2023
Tags
Royal Caribbean Cruises Ltd
JD/Com Inc
Steel Dynamics Inc
From
CNBC.com News
FDA advisors to weigh whether Alzheimer's drug Leqembi should receive full approval
June 09, 2023
Tags
Politics
Disease outbreaks
U/S/ Economy
From
CNBC.com News
Bernie Sanders says price of Alzheimer's treatment is unconscionable, calls on HHS to take action
June 07, 2023
Tags
Health care industry
Eisai Co Ltd
US: News
From
CNBC.com News
Jim Cramer expects defensive stocks to be resilient as debt ceiling talks drag on
May 15, 2023
Tags
Chipotle Mexican Grill Inc
Business
ONEOK Inc
From
CNBC.com News
Alzheimer's treatment Leqembi could cost Medicare up to $5 billion per year, study estimates
May 12, 2023
Tags
Health care industry
Eisai Co Ltd
US: News
From
CNBC.com News
Stocks making the biggest moves premarket: Starbucks, AMD, Pearson, PacWest & more
May 03, 2023
Tags
Advanced Micro Devices Inc
Western Alliance Bancorp
Eli Lilly and Co
From
CNBC.com News
Bipartisan attorneys general call on Medicare to cover Alzheimer's treatments
May 01, 2023
Tags
Politics
Disease outbreaks
U/S/ Economy
From
CNBC.com News
Alzheimer’s patients may wait years to get treated with new drugs, putting them at risk of more severe disease
April 30, 2023
Tags
Business News
Quanterix Corp
US: News
From
CNBC.com News
Alzheimer's: Medicare will cover Leqembi for all patients if FDA approves drug, CMS chief says
April 26, 2023
Tags
Health care industry
Eisai Co Ltd
Biotechnology
From
CNBC.com News
Biogen isn't concerned about competing with Eli Lilly in the Alzheimer’s drug space, CEO says
April 25, 2023
Tags
Business
Eli Lilly and Co
Health & Science
From
CNBC.com News
FDA grants accelerated approval for Biogen ALS drug that treats rare form of the disease
April 25, 2023
Tags
Pharmaceuticals
Companies
Health care industry
From
CNBC.com News
Alzheimer’s patients retain the benefits of Leqembi even when they stop the drug, Eisai says
April 06, 2023
Tags
Biotech and Pharmaceuticals
Breaking news
Science
From
CNBC.com News
Eli Lilly says experimental Alzheimer's drug reduces brain plaque in early study
April 05, 2023
Tags
Companies
Pharmaceuticals
Health care industry
From
CNBC.com News
FDA advisors reject Biogen's ALS drug for rare and aggressive form of the disease
March 22, 2023
Tags
Biogen Inc
Breaking news
Breaking News: Business
From
CNBC.com News
FDA staff says Biogen's ALS drug may have a 'clinical benefit' on a rare form of the disease
March 20, 2023
Tags
Business
Health & Science
Companies
From
CNBC.com News
Veterans' Health will cover Alzheimer's treatment Leqembi for some patients
March 13, 2023
Tags
Pandemics
US Economy
US Top News and Analysis
From
CNBC.com News
FDA will review Eisai's and Biogen's Alzheimer's treatment Leqembi with decision on full approval expected in early July
March 06, 2023
Tags
Health care industry
Coronavirus
Eisai Co Ltd
From
CNBC.com News
Medicare rejects Alzheimer's Association request for unrestricted coverage of treatments like Leqembi
February 23, 2023
Tags
Coronavirus
Health care industry
Eisai Co Ltd
From
CNBC.com News
Stocks making the biggest moves midday: Deere, Airbnb, AutoNation, Moderna and more
February 17, 2023
Tags
AutoNation Inc
Deere & Co
Finance
From
CNBC.com News
Senators call on Medicare to offer broad coverage of Alzheimer's treatments as public pressure grows
February 17, 2023
Tags
Biotechnology
Business News
Biogen Inc
From
CNBC.com News
Maker of promising Alzheimer's drug Leqembi expects full FDA approval this summer, expanded Medicare coverage
February 17, 2023
Tags
Pandemics
US Economy
US Top News and Analysis
From
CNBC.com News
Stocks making the biggest moves premarket: Kraft Heinz, Paramount, Airbnb, Tripadvisor and more
February 15, 2023
Tags
Airbnb Inc
FactSet Research Systems Inc
Taiwan Semiconductor Manufacturing Co Ltd
From
CNBC.com News
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.